Follow
Patrick Ryan
Patrick Ryan
Janssen Research and Development
Verified email at cornell.edu
Title
Cited by
Cited by
Year
Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers
G Hripcsak, JD Duke, NH Shah, CG Reich, V Huser, MJ Schuemie, ...
Studies in health technology and informatics 216, 574, 2015
10932015
Validation of a common data model for active safety surveillance research
JM Overhage, PB Ryan, CG Reich, AG Hartzema, PE Stang
Journal of the American Medical Informatics Association 19 (1), 54-60, 2012
4812012
Novel data‐mining methodologies for adverse drug event discovery and analysis
R Harpaz, W DuMouchel, NH Shah, D Madigan, P Ryan, C Friedman
Clinical Pharmacology & Therapeutics 91 (6), 1010-1021, 2012
4202012
Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership
PE Stang, PB Ryan, JA Racoosin, JM Overhage, AG Hartzema, C Reich, ...
Annals of internal medicine 153 (9), 600-606, 2010
4192010
A harmonized data quality assessment terminology and framework for the secondary use of electronic health record data
MG Kahn, TJ Callahan, J Barnard, AE Bauck, J Brown, BN Davidson, ...
Egems 4 (1), 2016
3842016
Characterizing treatment pathways at scale using the OHDSI network
G Hripcsak, PB Ryan, JD Duke, NH Shah, RW Park, V Huser, MA Suchard, ...
Proceedings of the National Academy of Sciences 113 (27), 7329-7336, 2016
3362016
Performance of pharmacovigilance signal‐detection algorithms for the FDA adverse event reporting system
R Harpaz, W DuMouchel, P LePendu, A Bauer‐Mehren, P Ryan, ...
Clinical Pharmacology & Therapeutics 93 (6), 539-546, 2013
2972013
Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis
MA Suchard, MJ Schuemie, HM Krumholz, SC You, RJ Chen, N Pratt, ...
The Lancet 394 (10211), 1816-1826, 2019
2892019
Feasibility and utility of applications of the common data model to multiple, disparate observational health databases
EA Voss, R Makadia, A Matcho, Q Ma, C Knoll, M Schuemie, FJ DeFalco, ...
Journal of the American Medical Informatics Association 22 (3), 553-564, 2015
2462015
Interpreting observational studies: why empirical calibration is needed to correct p‐values
MJ Schuemie, PB Ryan, W DuMouchel, MA Suchard, D Madigan
Statistics in medicine 33 (2), 209-218, 2014
2122014
Feasibility of using real-world data to replicate clinical trial evidence
VL Bartlett, SS Dhruva, ND Shah, P Ryan, JS Ross
JAMA network open 2 (10), e1912869-e1912869, 2019
2082019
Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 …
PB Ryan, JB Buse, MJ Schuemie, F DeFalco, Z Yuan, PE Stang, JA Berlin, ...
Diabetes, Obesity and Metabolism 20 (11), 2585-2597, 2018
2002018
Evaluating the impact of database heterogeneity on observational study results
D Madigan, PB Ryan, M Schuemie, PE Stang, JM Overhage, ...
American journal of epidemiology 178 (4), 645-651, 2013
2002013
Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership
PB Ryan, D Madigan, PE Stang, J Marc Overhage, JA Racoosin, ...
Statistics in medicine 31 (30), 4401-4415, 2012
1922012
Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data
JM Reps, MJ Schuemie, MA Suchard, PB Ryan, PR Rijnbeek
Journal of the American Medical Informatics Association 25 (8), 969-975, 2018
1802018
A curated and standardized adverse drug event resource to accelerate drug safety research
JM Banda, L Evans, RS Vanguri, NP Tatonetti, PB Ryan, NH Shah
Scientific data 3 (1), 1-11, 2016
1802016
Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled …
JCE Lane, J Weaver, K Kostka, T Duarte-Salles, MTF Abrahao, H Alghoul, ...
MedRxiv, 2020
1772020
Renin–angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis
DR Morales, MM Conover, SC You, N Pratt, K Kostka, T Duarte-Salles, ...
The Lancet Digital Health 3 (2), e98-e114, 2021
1452021
Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study
X Li, A Ostropolets, R Makadia, A Shoaibi, G Rao, AG Sena, ...
bmj 373, 2021
1422021
Defining a reference set to support methodological research in drug safety
PB Ryan, MJ Schuemie, E Welebob, J Duke, S Valentine, AG Hartzema
Drug safety 36, 33-47, 2013
1412013
The system can't perform the operation now. Try again later.
Articles 1–20